← Leaderboards
Kim A Boggess
University Of North Carolina Chapel Hill
$10,215,110
Attributed
$19,080,784
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,080,784 · 10
By mechanism
R01$8,301,669 · 2
U01$6,955,634 · 1
K12$1,947,358 · 1
T32$795,954 · 1
R21$394,252 · 1
K08$378,187 · 1
Top collaborators
- Michelle Meyer10 shared
- Diane C Berry7 shared
- Ashley Nicole Battarbee2 shared
- Rebecca Gersnoviez Clifton2 shared
- Alan Thevenet N. Tita2 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- William J Arendshorst$8,268,789
- Oliver Smithies$18,314,429
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanPregnant WomenFuturePregnancyAffectInfantMothersPre-EclampsiaPreventBirthCohortAdverse OutcomePerinatal OutcomesPublic HealthInnovationGestational AgeCharacteristicsRecommendationObesityEnrollmentWomen&AposMultidisciplinaryEthnic OriginS Health
Grant awards (38)
Adjunctive Azithromycin Prophylaxis for Scheduled/Prelabor Cesarean Delivery$3,341,494
U01 · FY2025 · HD
Adjunctive Azithromycin Prophylaxis for Scheduled/Prelabor Cesarean Delivery$3,614,140
U01 · FY2024 · HD
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$668,109
R01 · FY2024 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$192,755
R01 · FY2024 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$176,657
R01 · FY2024 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$686,129
R01 · FY2023 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$192,755
R01 · FY2023 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$176,346
R01 · FY2023 · HL
Structural racism and cardiovascular disease risk in pregnant women and their infants$159,326
R01 · FY2023 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$691,361
R01 · FY2022 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$177,590
R01 · FY2022 · HL
Arterial stiffness in mother/infant dyads: Life course approach to prevent cardiovascular disease$693,798
R01 · FY2021 · HL
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD)$652,208
R01 · FY2021 · HD · contact PI
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD)$908,642
R01 · FY2020 · HD · contact PI
Medical optimization & management of pregnancies with overt type 2 diabetes (MOMPOD) - Admin Supplement 3: Effect of Overt Type 2 Diabetes and Metformin Treatment on Placental Transport Proteins$165,167
R01 · FY2020 · HD · contact PI
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD)$924,922
R01 · FY2019 · HD · contact PI
UNC BIRCWH$515,389
K12 · FY2019 · HD · contact PI
Fetal metabolic consequences of late preterm steroid exposure$77,750
R03 · FY2019 · HD · contact PI
UNC BIRCWH$478,950
K12 · FY2018 · HD · contact PI
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD)$80,606
R01 · FY2018 · HD · contact PI
Fetal metabolic consequences of late preterm steroid exposure$77,750
R03 · FY2018 · HD
Phase II Study of Nicotinamide (vitamin B3-amide) in Early-Onset Preeclampsia$76,000
R03 · FY2018 · HD · contact PI
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD)$905,815
R01 · FY2017 · HD · contact PI
UNC BIRCWH$324,453
K12 · FY2017 · HD · contact PI
UNC BIRCWH$165,604
K12 · FY2017 · HD · contact PI
Phase II Study of Nicotinamide (vitamin B3-amide) in Early-Onset Preeclampsia$76,000
R03 · FY2017 · HD · contact PI
Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD)$849,483
R01 · FY2016 · HD · contact PI
UNC BIRCWH$358,922
K12 · FY2016 · HD · contact PI
UNC BIRCWH$104,040
K12 · FY2015 · HD · contact PI
Training in Epidemiology and Clinical Trials (TECT)$72,020
T32 · FY2015 · HD · contact PI
Training in Epidemiology and Clinical Trials (TECT)$366,059
T32 · FY2014 · HD · contact PI
Training in Epidemiology and Clinical Trials (TECT)$357,875
T32 · FY2013 · HD · contact PI
Understanding Barriers to Oral Health Care In Pregnancy: The First Step to Improv$177,848
R21 · FY2008 · DE · contact PI
VALIDATION OF SELF-REPORT TOOL TO SCREEN FOR PERIODONTAL DISEASE AMONG PREGNANT$230
M01 · FY2008 · RR · contact PI
Understanding Barriers to Oral Health Care In Pregnancy: The First Step to Improv$216,404
R21 · FY2007 · DE · contact PI
EFFECT OF CHRONIC INFECTION ON PLACENTAL DEVELOPMENT$126,735
K08 · FY2005 · HD
EFFECT OF CHRONIC INFECTION ON PLACENTAL DEVELOPMENT$125,969
K08 · FY2004 · HD
EFFECT OF CHRONIC INFECTION ON PLACENTAL DEVELOPMENT$125,483
K08 · FY2003 · HD